Schwarz Pharma said on Friday that it had reacquired all the remaining rights to the Parkinson’s disease treatment, rotigotine, from Aderis Pharmaceuticals. However, the buy comes with a €58 million euro price tag, and the German firm, which had aimed to break even this year [[27/10/04c]], is now expecting to record a €58 million net loss for 2005.

Schwarz said that the acquisition made “strong financial sense” as it buys out future royalty and milestone obligations, which enhance the firm’s profitability once the drug hits the market.

Rotigotine is currently being reviewed by regulators on both sides of the Atlantic and will be sold under the brand name of Neupro once approved [[12/10/04e]].